Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Generic 'Breakthrough' Pathway Could Have Unintended Consequences

Executive Summary

CDER Director Woodcock warns that incentivizing ANDA development with breakthrough-style approach could have unintended consequences, such as more citizen petitions designed to delay generic availability.

You may also be interested in...



FDA User Fee Hearing Hijacked By US Health Care Reform Arguments

Democrats argue generic competition alone cannot fix drug pricing problem as senators attempt to pull FDA into Obamacare repeal and replace debate.

REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing

Although panelists expressed concerns about REMS misuse as barrier to competition, Republicans did not appear interested in the topic.

Citizen Petitions Targeting ANDAs Recede, But Concerns Over Resources Remain

FDA worries about diverting resources to respond to 505(q) petitions, despite receiving lowest number in fiscal year 2015 since it began tracking requests.

Topics

UsernamePublicRestriction

Register

GB002125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel